FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1920857594> ?p ?o ?g. }

• W1920857594 endingPage "33" @default.
• W1920857594 startingPage "10" @default.
• W1920857594 abstract "The goal of this chapter is to discuss the importance of preclinical evaluation of potential therapies for neurological disorders in animal models that mimic the target human disorder as a prelude to the translation of these into clinical trials. The scope of neurological and/or neurosurgical disorders that could be considered herein includes both acute neurological insults as well as chronic conditions such as epilepsy, neuropathic pain and the neurodegenerative disorders, primarily Alzheimer’s disease, Parkinson’s disease and the motor neuron diseases, mainly amyotrophic lateral sclerosis. Animal models for all of these conditions have been devised and used to evaluate potential therapies. However, a single chapter cannot possibly do justice to this wide range of disorders and associated models. Thus, in order to keep the subject of neurological animal studies manageable, the focus of this chapter will be on models and basic principles of preclinical evaluation of therapies in the context of acute neurological injuries including stroke, cardiac arrest and cardiopulmonary resuscitation (CA/CPR), traumatic brain injury (TBI) and spinal cord injury (SCI). These acute insults represent 4 of the most catastrophic consequences that human beings can suffer. Furthermore, the discussion of how to test therapies in models of these conditions will be couched primarily in relation to pharmacological therapies. However, many, if not all principles that define a thorough preclinical evaluation of drugs in animal models are in fact equally applicable to gene and cellular transplant therapies.There are approximately 750,000 strokes per year in the US, most, but certainly not all, affecting the elderly population. About 85% of strokes are ischemic in nature, involving a thromboembolic blockage of a brain artery; up to 15% of strokes are hemorrhagic. There are 2 types of hemorrhagic strokes: intracerebral hemorrhage (ICH) when blood is released into brain parenchyma producing brain damage by triggering brain edema (swelling) and mass effects, resulting in secondary ischemia within the brain tissue, and subarachnoid hemorrhage (SAH) when blood is released into the subarachnoid space from an aneurysm ballooning out from one of the major arteries, also causing a secondary ischemic insult from induction of delayed cerebral vasospasm peaking at 4–7 days after SAH. There are about 30,000 aneurysmal SAH per year in the US with a 2:1 female:male preponderance.Cardiac arrest strikes about 600,000 people per year in the USA and leads to high mortality and poor neurological outcome. Many survivors of CA/CPR have moderate to severe neurological deficits many months following the event. Survival rates following CA/CPR have not changed for decades despite improvements in resuscitation techniques. The lack of effective treatment options to ameliorate reperfusion injury in the postresuscitation period likely accounts for the disappointing survival rates. Recently, however, induction of mild hypothermia in unresponsive cardiac arrest survivors showed improved neurological outcome and 6-month survival. This was the first demonstration in humans that development of brain injury after CA/CPR could be positively influenced by a postischemic intervention.There are an estimated 1.5 million cases per annum of TBI in the US, ranging from mild to severe. Although most TBI cases are mild in severity, about 58,000 are severe (Glasgow Coma Score: 3–8) and 64,000 moderate (Glasgow Coma Score: 9–12) and such individuals often require intensive medical treatment and extended recovery periods. Further, there are about 11,000 new cases of SCI each year in the US with an overall prevalence of approximately 250,000. Although TBI and SCI affect active individuals of any age, most occur in young adults in the second and third decades of life. Moreover, the majority of stroke, TBI and SCI patients now survive their neurological insults due to improvements in emergency, neurological intensive care and surgical treatments. Nevertheless, the need for intensive rehabilitation and the reality of prolonged disability exacts a significant toll on the individual, his or her family and society. Effective ways of maintaining or recovering function could markedly improve the outlook for persons with these insults by enabling higher levels of independence and productivity." @default.
• W1920857594 created "2016-06-24" @default.
• W1920857594 creator A5002997691 @default.
• W1920857594 creator A5060319184 @default.
• W1920857594 date "2009-01-01" @default.
• W1920857594 modified "2023-10-15" @default.
• W1920857594 title "Role of Animal Studies in the Design of Clinical Trials" @default.
• W1920857594 cites W1569061064 @default.
• W1920857594 cites W1854660019 @default.
• W1920857594 cites W1965582720 @default.
• W1920857594 cites W1973590627 @default.
• W1920857594 cites W1975724680 @default.
• W1920857594 cites W1982392703 @default.
• W1920857594 cites W1982892406 @default.
• W1920857594 cites W1984640486 @default.
• W1920857594 cites W1986963388 @default.
• W1920857594 cites W1987131334 @default.
• W1920857594 cites W1987322659 @default.
• W1920857594 cites W1990333580 @default.
• W1920857594 cites W1992877627 @default.
• W1920857594 cites W2001062556 @default.
• W1920857594 cites W2002348401 @default.
• W1920857594 cites W2003222772 @default.
• W1920857594 cites W2013833441 @default.
• W1920857594 cites W2016703443 @default.
• W1920857594 cites W2016997908 @default.
• W1920857594 cites W2025832684 @default.
• W1920857594 cites W2025923976 @default.
• W1920857594 cites W2029973048 @default.
• W1920857594 cites W2030084515 @default.
• W1920857594 cites W2031489662 @default.
• W1920857594 cites W2031644015 @default.
• W1920857594 cites W2036039593 @default.
• W1920857594 cites W2036290144 @default.
• W1920857594 cites W2041102637 @default.
• W1920857594 cites W2042685592 @default.
• W1920857594 cites W2045663952 @default.
• W1920857594 cites W2048835444 @default.
• W1920857594 cites W2054336547 @default.
• W1920857594 cites W2058329822 @default.
• W1920857594 cites W2059982861 @default.
• W1920857594 cites W2063468575 @default.
• W1920857594 cites W2065094515 @default.
• W1920857594 cites W2076645884 @default.
• W1920857594 cites W2077826388 @default.
• W1920857594 cites W2086070682 @default.
• W1920857594 cites W2087113551 @default.
• W1920857594 cites W2095410798 @default.
• W1920857594 cites W2098798964 @default.
• W1920857594 cites W2104730217 @default.
• W1920857594 cites W2121903406 @default.
• W1920857594 cites W2135637406 @default.
• W1920857594 cites W2136280619 @default.
• W1920857594 cites W2142047675 @default.
• W1920857594 cites W2144430198 @default.
• W1920857594 cites W2161365799 @default.
• W1920857594 cites W2170645579 @default.
• W1920857594 cites W2172297004 @default.
• W1920857594 cites W2205987263 @default.
• W1920857594 cites W2620428105 @default.
• W1920857594 cites W2116301028 @default.
• W1920857594 doi "https://doi.org/10.1159/000209470" @default.
• W1920857594 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2811045" @default.
• W1920857594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19478492" @default.
• W1920857594 hasPublicationYear "2009" @default.
• W1920857594 type Work @default.
• W1920857594 sameAs 1920857594 @default.
• W1920857594 citedByCount "24" @default.
• W1920857594 countsByYear W19208575942012 @default.
• W1920857594 countsByYear W19208575942014 @default.
• W1920857594 countsByYear W19208575942015 @default.
• W1920857594 countsByYear W19208575942016 @default.
• W1920857594 countsByYear W19208575942017 @default.
• W1920857594 countsByYear W19208575942018 @default.
• W1920857594 countsByYear W19208575942020 @default.
• W1920857594 countsByYear W19208575942021 @default.
• W1920857594 countsByYear W19208575942022 @default.
• W1920857594 crossrefType "book-chapter" @default.
• W1920857594 hasAuthorship W1920857594A5002997691 @default.
• W1920857594 hasAuthorship W1920857594A5060319184 @default.
• W1920857594 hasBestOaLocation W19208575942 @default.
• W1920857594 hasConcept C126322002 @default.
• W1920857594 hasConcept C15744967 @default.
• W1920857594 hasConcept C535046627 @default.
• W1920857594 hasConcept C71924100 @default.
• W1920857594 hasConceptScore W1920857594C126322002 @default.
• W1920857594 hasConceptScore W1920857594C15744967 @default.
• W1920857594 hasConceptScore W1920857594C535046627 @default.
• W1920857594 hasConceptScore W1920857594C71924100 @default.
• W1920857594 hasLocation W19208575941 @default.
• W1920857594 hasLocation W19208575942 @default.
• W1920857594 hasLocation W19208575943 @default.
• W1920857594 hasLocation W19208575944 @default.
• W1920857594 hasOpenAccess W1920857594 @default.
• W1920857594 hasPrimaryLocation W19208575941 @default.
• W1920857594 hasRelatedWork W1506200166 @default.
• W1920857594 hasRelatedWork W1995515455 @default.
• W1920857594 hasRelatedWork W2048182022 @default.

• next